NKX019

· Nkarta, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for NKX019, covering 2026-03-09 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus [Phase 1]